TRAJENTA 5MG 10S

About

TRAJENTA 5MG contains Linagliptin, an oral antidiabetic medication belonging to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors. It is used to improve glycemic control in adults with type 2 diabetes mellitus. Linagliptin works by inhibiting the enzyme DPP-4, which is responsible for the inactivation of incretin hormones, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).

By preserving active incretin levels, TRAJENTA enhances glucose-dependent insulin secretion from pancreatic beta cells and reduces glucagon secretion from pancreatic alpha cells. This leads to lower blood glucose concentrations, particularly after meals. A key advantage of Linagliptin is its primary excretion via the enterohepatic system, meaning no dose adjustment is required for patients with renal impairment, making it a suitable option for a broad range of patients with type 2 diabetes.

Uses

• Improvement of glycemic control in adults with type 2 diabetes mellitus.
• Used as monotherapy or in combination with other antidiabetic agents.
• Helps to lower elevated blood sugar levels.
• Part of a comprehensive diabetes management plan including diet and exercise.

Directions For Use

Take one tablet orally once daily, with or without food. Swallow the tablet whole with water.

Benefits

• Effectively lowers blood glucose levels.
• Low risk of hypoglycemia when used as monotherapy.
• No dose adjustment needed for renal impairment.
• Can be used in combination with other antidiabetic drugs.
• Convenient once-daily dosing.
• Generally well-tolerated.

Side Effects

• Nasopharyngitis
• Headache
• Cough
• Diarrhea
• Hypoglycemia (especially with sulfonylurea or insulin)
• Pancreatitis (rare)
• Joint pain (arthralgia)
• Rash
• Urticaria
• Angioedema
• Bullous pemphigoid (rare)
• Muscle pain (myalgia)

Safety Measures

• Alcohol - Moderate alcohol consumption is generally acceptable, but excessive intake can affect blood sugar levels and should be discussed with a healthcare provider.
• Pregnancy - Not recommended during pregnancy due to insufficient data. Use only if potential benefit justifies the potential risk to the fetus.
• Breastfeeding - It is unknown if Linagliptin is excreted in human milk. A decision should be made whether to discontinue nursing or discontinue the drug.
• Liver - No dose adjustment is required for patients with hepatic impairment.
• Kidney - No dose adjustment is required for patients with renal impairment, including end-stage renal disease.
• Lung - No specific contraindications or significant interactions related to lung conditions are typically noted for TRAJENTA.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.